Abstract
Chronic pain remains a serious medical problem that is often refractory to available treatments. The Nerve Targeting Drug Delivery System (NTDDS) utilizes genetically engineered, replication-defective herpes simplex virus (HSV) as a vehicle to deliver a therapeutic gene directly to dorsal root ganglion (DRG) neurons from a skin inoculation. We have previously reported the results of a Phase I clinical trial of NP2, a preproenkephalin (PENK) expressing NTDDS vector. The PENK gene produces opioid peptides, leu- and met-enkephalin, that are endogenous high affinity agonists for the delta opioid receptor.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
